Innovative, Fundable, Early Stage Opportunities
Join us to hear from the 2015 Class of Life Sciences Summit Emerging Companies. Each company was nominated, reviewed and invited to present based upon their innovative science and the quality of their management team. They will present before a panel of ‘Pitch Doctors’, early stage VCs and investors, corporate VCs, strategic partners and other investors and advisors, who will ask questions about their science and strategy.
Preliminary list. Please check back often, as companies are being added on a regular basis.
2015 Presenting Companies
 |
Alitair Pharmaceuticals, Inc., Morristown NJ: A specialty pharmaceutical company with a focus on the respiratory space, currently developing two Orphan drugs for bronchiectasis. |
|
|
Aridis Pharmaceuticals, San Jose, CA: Developing a suite of anti-infective monocolonal antibodies using a discovery platform technology to target infectious diseases including nosocomial and ventilator-associated Pneumonia, MRSA, and Pseudomonas aeruginosa infections that affect Cystic Fibrosis patients. |
|
|
BMSEED, LLC, Tempe, AZ: Developed a monitoring device for traumatic brain injury that utilizes a stretchable gold film that monitors electrophysiological activity in cells and tissue. |
|
|
Cell Source, Inc.,New York, NY: Utilizing breakthrough immune tolerance and organ regeneration technologies to revolutionize transplantation, cancer treatment and reversal of vital organ disease. |
|
|
Cenna Biosciences, San Diego, CA: Developing a novel disease-modifying small peptide to block amyloid production in Alzheimer’s Disease. |
|
|
Cloud Pharmaceuticals, Research Triangle Park, NC: Uses the power of cloud computing, quantum mechanics, and molecular property simulation to inform and improve rational drug discovery and design. |
|
|
Codagenix Inc., Stony Brook, NY: Developing live attenuated vaccines using unique algorithm to restructure viral genomes, resulting in highly attenuated vaccine strains that are therapeutically effective at doses much smaller than current therapies. |
|
|
DepyYmed, Cold Spring Harbor, NY: Has developed Trodusquemine – a highly selective inhibitor of the critical protein tyrosine phosphatase 1B (PTP1B) enzyme with applications in oncology, diabetes, and obesity and is currently being developed as a therapy for HER2-positive breast cancer. |
|
|
Efferent Labs, Buffalo, NY: Developing implantable biosensors utilizing living cells to assess cellular function in vivo which has multiple applications including preclinical R&D, clinical testing, oncology, cardiology, and metabolic diseases. |
|
|
Envisagenics, Cold Spring Harbor, NY: Developing a cloud-based software platform for the analysis of splicing, translating NextGen sequencing data into BioPharma R&D intelligence through a SaaS business model. |
|
|
Epigen Biosciences, Inc., San Diego, CA: Utilizing advanced lead optimization methods including computational design, scaffold-hopping, focused library synthesis and screening to discover novel assets for unmet medical needs with a focus on new treatments for pain. |
|
|
Escend Pharmaceuticals, Inc., Menlo Park, CA: Developing small molecule therapeutics for cancer orphan indications, including therapeutics that kill cancer stem cells in chronic myelogenous leukemia and related hematologic malignancies. |
|
|
GeneSegues Therapeutics, Minnetonka, MN: developing next generation of targeted drugs for cancer treatment that combines innovative RNAi therapeutics with novel sub-50 nanometer capsule technology that increases the amount of RNAi drug delivered to both primary and metastatic tumors. |
|
|
Genomic Expression, New York, NY: Developing sequence-based cancer diagnostics using RNA markers to predict chemo, immune, and targeted therapy responsiveness. |
|
|
Gismo Therapeutics, Inc., Lexington, KY: Developing first-in-class therapeutics for neurodegenerative diseases using Glycosaminoglycan-Interacting Small Molecules (GISMO) platform technology to target GAG-amyloid complexes involved in Alzheimer’s and Parkinson’s diseases. |
|
|
Global Genomics Group, Atlanta, GA: Leveraging molecular profiles of human health, precision phenotyping, integrated omics, and advanced analytics to develop life changing diagnostics and therapeutics. |
|
|
Inflammatory Response Research Inc., Santa Barbara, CA: Developing therapeutics for the treatment of inflammatory disorders and conditions including influenza, common cold, and traumatic brain injury. |
|
|
Innovimmune, Brooklyn, NY: Developing oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune and ImmunoInflammatory Diseases. |
|
|
Intrommune Therapeutics, New York, NY: Developing a revolutionary new treatment platform for food allergies that is safe, effective and convenient. Intrommune’s first product is a therapy for patients who suffer from peanut allergy. |
|
|
Kenkodo, Potsdam, Germany: Developing a cloud based, personal digital health monitor that measures metabolic changes in blood samples and by tracking lifestyle information submitted via the Kenkodo smartphone application. |
|
|
Linus Oncology, Miami, FL: Developing a phase II ready first-in-class indenoisoquinoline anti-cancer therapeutics as successor agents to the Topoisomerase I inhibitor Camptothecin. |
 |
Memgen, Houston, TX: Clinical-stage biotech company. Our ISF35 cancer immunotherapy with checkpoint inhibitors cures 40% of mice with B16 melanoma tumor. Phase I/II clinical trial of ISF35 and Keytruda in refractory metastatic melanoma starting February 2016 at MD Anderson Cancer Center. |
|
|
NeuroGenetic Pharmaceuticals, Del Mar, CA: Developing a novel approach to the treatment and prevention of Alzheimer’s disease by modulating the activity of the key enzymes involved in the production of Amyloid beta 42, a primary component of amyloid plaques. |
|
|
NeurOp, Inc., Atlanta, GA: Small molecule drug discovery company targeting various subunits of N-methyl-D-aspartate (NMDA) receptors for the treatment and prevention of CNS disorders including stroke (cerebral ischemia), Alzheimer’s, Parkinson’s, schizophrenia, depression, and neuropathic pain. |
|
|
PathMaker Neurosystems, Inc., Boston, MA: Commercializing breakthrough advances in non-invasive Trans-Spinal Direct Current Stimulation (tsDCS) for the treatment of patients with neuromotor disorders including paralysis, muscle weakness and muscle tone disorders. |
 |
PHD Biosciences, New York, NY: Developing small molecule targeted enzyme inhibitors for oncology and sickle cell disease that operate by unique mechanisms of action from all known therapeutics. |
|
|
Phoenix Nest, Inc., Brooklyn, NY: Developing treatments for Sanfilippo Syndrome IIIC and IIID, using approaches that include enzyme replacement and chaperone therapies. |
|
|
PixarBio, Medford, MA: Developing a novel drug delivery platform to achieve sustained release of non-opiate drugs to treat post-operative, acute and chronic pain. |
|
|
Renovo Neural, Inc., Cleveland, Ohio: Using a highly innovative screening technology to identify novel small molecules that stimulate neural remyelination for the treatment of multiple sclerosis. |
|
|
Rgenix, New York, NY: Designing first-in-class oncology therapeutics using discovery platform to identify and validate novel post-transcriptionally regulated targets. |
|
|
Riparian Pharma, Cambridge, MA: Developing small molecule activators of vasoprotective pathways that have the potential to treat a wide range of inflammatory diseases including atherosclerosis, cardiovascular disease, cirrhosis and organ transplantation. |
|
|
Savara Pharmaceuticals, Austin, TX: Developing small molecule inhalation therapeutic for treatment of MRSA infections in cystic fibrosis and chronic care patients. |
|
|
Siamab Therapeutics, Newton, MA: Developing novel cancer immunotherapies. Siamab has developed a platform of technologies that enable the rapid discovery and development of therapeutic antibodies that bind to a novel class of carbohydrate antigens present on cancer cells. |
|
|
Susavion Biosciences Inc., Tempe, AZ: A cancer immunotherapy company dedicated to the design of novel peptides for the treatment of cancer and viral infections. |
|
|
Symbiotic Health, New York, NY: Developing a treatment for C. difficile infections using a novel targeted delivery method of therapeutic bacteria in stable oral capsules to restore the microbiome of the gastrointestinal tract. |
|
|
SynVivo, Houston, TX: Developing a proprietary microfluidic chip platform technology for use in oncology, neurology and inflammation studies that simulates the circulation inside any tissue with respect to flow, shear, and pressure. |
|
|
SynZyme Technologies LLC, Sioux Falls, SD: Developing therapeutic agents for the treatment of hypoxia and impaired blood flow using their platform superoxide dismutase mimetic nanoparticles to control vascular superoxide. This platform has demonstrated efficacy in preclinical models of stroke, in traumatic brain injury accompanied by hemorrhagic shock, and in sickle cell disease. Additional indications include use in pre-hospital emergency care and in cancer therapy. |
|
|
TargaGenix, Inc. Stony Brook, NY: Developing a novel therapy effective against taxane-resistant tumors by targeting cancer stem cells and bulk tumor cells. |
|
|
Theragnostic Technologies, Stony Brook, NY: Focusing on research and development of high performance multifunctional nanotechnology-enabled materials and devices. |
|
|
Traverse Biosciences, Stony Brook, NY: Commercializing novel drug candidates for the treatment of inflammatory diseases and related conditions affecting humans and companion animals. |
|
|
Vala Sciences, San Diego, CA: Developing a miniaturized, cell-based optogenetic multiparametric assay for high-throughput cardiotoxicity testing in an automated platform. |
|
|
Zoetic Pharmaceuticals, Buffalo, NY: Developing a nanoparticle-based platform technology to enhance the safety and efficacy of biotherapeutics by reducing immunogenicity and extending the half-life of IV injected biotherapeutics. |
Note about the presenting companies:
Companies selected to present at the Life Sciences Summit have raised $15 million or less with pre-clinical to Phase 2A assets.